Radiopharm Receives Strategic Investment for up to A$18 million
June 20, 2024 20:41 ET
|
Radiopharm Theranostics
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19...
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
October 09, 2023 07:27 ET
|
Radiopharm Theranostics
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic...
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
August 24, 2023 08:00 ET
|
Radiopharm Theranostics
SYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic...
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
May 09, 2023 07:30 ET
|
Radiopharm Theranostics
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high unmet needPotential...
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
April 17, 2023 07:30 ET
|
Radiopharm Theranostics
SYDNEY, Australia, April 17, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...
Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit
March 28, 2023 07:30 ET
|
Radiopharm Theranostics
SYDNEY, Australia, March 28, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
March 03, 2023 08:41 ET
|
Radiopharm Theranostics
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
March 03, 2023 07:30 ET
|
Radiopharm Theranostics
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both...
Radiopharm Theranostics Initiates Process for Nasdaq Listing
February 14, 2023 08:00 ET
|
Radiopharm Theranostics
Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023 SYDNEY, Australia, Feb. 14, 2023 ...